Biogen’s Tecfidera-fueled revenue up 21 percent
July 25, 2013 at 12:14 PM EDT
So far, Biogen Idec (Nasdaq: BIIB) appears to be exceeding the sky-high expectations for the launch of its newest multiple sclerosis drug, Tecfidera, in March...
